Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Protambbody

Financiado

Proteasomal degradation of toxic intracellular amyloid-beta protein by nanobody-...

Proteasomal degradation of toxic intracellular amyloid-beta protein by nanobody-enabled proximity to ubiquitin ligase The amyloid-beta (Aβ) protein arises from the sequential proteolytic cleavage of Aβ precursor protein (APP). The accumulation of Aβ oligomers has been regarded as the causal factor of Alzheimer’s disease (AD). Basal metabolic prod... ver más

30/06/2025

HELSINGIN YLIOPIST...

269K€

Presupuesto del proyecto: 269K€

Líder del proyecto

HELSINGIN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-06-08

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

HELSINGIN YLIOPISTO

269.42K€ | Lider

ROCHE DIAGNOSTICS GMBH

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PCI2024-153438 Materiales para biomedicina 294K€ Cerrado

SAF2016-75768-R ENFERMEDADES DE ALZHEIMER Y PARKINSON: DEGENERACION NEURONAL... 109K€ Cerrado

nanoIR4AD Infrared nanospectroscopy to understand and combat Alzheimer... 207K€ Cerrado

SAF2012-35226 ESTRUCTURA Y DINAMICA DE AGREGADOS DE LA PROTEINA B-AMILOIDE... 211K€ Cerrado

PGC2018-096335-B-I00 INVESTIGANDO LA AGREGACION AMILOIDE DE ALFA-SINUCLEINA EN LA... 168K€ Cerrado

RYC-2011-07873 DEVELOPMENT OF DRUG DISCOVERY STRATEGIES THAT TARGET AMYLOID... 184K€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2022-06-08
Fecha Fin: 2025-06-30

Líder del proyecto

HELSINGIN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 269K€

Descripción del proyecto The amyloid-beta (Aβ) protein arises from the sequential proteolytic cleavage of Aβ precursor protein (APP). The accumulation of Aβ oligomers has been regarded as the causal factor of Alzheimer’s disease (AD). Basal metabolic production of the Aβ peptide is typical in healthy people, and its production rate is normally lower than its rate of clearance. In AD, the uncontrolled accumulation of toxic forms of Aβ stemming from problems in its clearance and degradation results in memory loss, chronic neuroinflammation and neurodegeneration. AD is a leading cause of disability and death both in Europe and the world, and currently has no cure or clinically-proven disease-modifying therapies. There are over 10 million new cases of dementia each year worldwide (up to 80% of which are due to AD), implying one new case every 3.2 seconds. In Europe, about 10 million people currently suffer from this disease and about 50 million in the world; with these estimates projected to double by 2050. Thus, the identification of novel disease-modifying therapies has become very critical to eradicating AD from Europe and the world. My project proposes a radically novel approach in the AD field of utilizing the body’s cellular waste disposal system to selectively degrade Aβ peptide, the causative agent of AD. This is in sharp contrast to the current approach of immunization against the Aβ peptide, which has repeatedly failed to yield any cure or disease-modifying therapies for AD. This project will aim to identify the specific cytotoxic Aβ peptides responsible for neuroinflammation and neurodegeneration in human induced pluripotent stem cells and target these peptides for degradation by the ubiquitin proteasome system. Emphasis will be on the cytotoxic Aβ peptides of intracellular origin as emerging targets in AD. This research will be conducted at the University of Helsinki, Finland, followed by a non-academic placement at Roche Diagnostics GmbH.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores